A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature Metabolism

ADA 2026 Scientific Sessions: New GLP-1 Drugs and Diabetes Research Highlights

In this JAMA Medical News podcast, Jennifer Abbasi interviews Dr. Rita Kalyani, the ADA's Chief Scientific and Medical Officer, about key hi

ADA 2026: New GLP-1 Oral Drug, Semaglutide-Amylin Combo, and Chinese Mazdutide Data Highlighted

An interview with Dr. Rita Kalyani, the ADA's chief scientific and medical officer, discussing key research presented at the ADA 2026 Scient

Pfizer's Early 1990s Decision to Abandon Promising GLP-1 Therapy Development

The article reveals previously untold history about early GLP-1 drug development in the late 1980s and early 1990s. The author was part of w

Biased Dual-Agonists of GLP-1 and Glucagon Receptors Developed Through Conserved Aspartate Mutation

This article describes a scientific discovery where researchers engineered biased dual-agonists of the glucagon-like peptide 1 receptor (GLP

Eli Lilly’s Michael Kopach says retatrutide leads in obesity treatment and CMC innovation

Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption

This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica